Source: Pediatric Blood Cancer. Conference titles: Congress of the International Society of Paediatric Oncology. Unidade: FM
Subjects: NEUROBLASTOMA, CRIANÇAS, CINTILOGRAFIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ODONE FILHO, Vicente et al. Feasibility of therapeutic 1131 metaiodobenzylguanidine (MIBG) previous to blood stem cell, collection as "purging in vivo" for high-risk neuroblastomas (HRNB). 2014, Anais.. Hoboken: Faculdade de Medicina, Universidade de São Paulo, 2014. p. S207. Disponível em: http://onlinelibrary.wiley.com/doi/10.1002/pbc.25314/pdf. Acesso em: 02 jun. 2024.APA
Odone Filho, V., Almeida, M. T. A., Buchpiguel, C., Azambuja, A. M. P., Vince, C. S. C., Brumatti, M., et al. (2014). Feasibility of therapeutic 1131 metaiodobenzylguanidine (MIBG) previous to blood stem cell, collection as "purging in vivo" for high-risk neuroblastomas (HRNB). In Pediatric Blood Cancer (Vol. 61, p. S207). Hoboken: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://onlinelibrary.wiley.com/doi/10.1002/pbc.25314/pdfNLM
Odone Filho V, Almeida MTA, Buchpiguel C, Azambuja AMP, Vince CSC, Brumatti M, Neves NSH, Batista GLF, Maluf Junior PT, Cristofani LMC. Feasibility of therapeutic 1131 metaiodobenzylguanidine (MIBG) previous to blood stem cell, collection as "purging in vivo" for high-risk neuroblastomas (HRNB) [Internet]. Pediatric Blood Cancer. 2014 ; 61( S2): S207.[citado 2024 jun. 02 ] Available from: http://onlinelibrary.wiley.com/doi/10.1002/pbc.25314/pdfVancouver
Odone Filho V, Almeida MTA, Buchpiguel C, Azambuja AMP, Vince CSC, Brumatti M, Neves NSH, Batista GLF, Maluf Junior PT, Cristofani LMC. Feasibility of therapeutic 1131 metaiodobenzylguanidine (MIBG) previous to blood stem cell, collection as "purging in vivo" for high-risk neuroblastomas (HRNB) [Internet]. Pediatric Blood Cancer. 2014 ; 61( S2): S207.[citado 2024 jun. 02 ] Available from: http://onlinelibrary.wiley.com/doi/10.1002/pbc.25314/pdf
